impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Reviews

 

Rationale underlying the measurement of fractional exhaled nitric oxide in systemic sclerosis patients

1, 2, 3, 4, 5, 6, 7, 8, 9, 10

 

  1. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy. rizzi.maurizio@asst-fbf-sacco.it
  2. L. Sacco Department of Biomedical Sciences, University of Milan, Italy.
  3. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  4. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  5. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  6. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  7. Respiratory Unit, Luigi Sacco University Hospital Milan, Italy.
  8. Rheumatology Unit, Department of Internal and Experimental Medicine, University of Messina, Italy.
  9. Rheumatology Unit, Luigi Sacco University Hospital, Milan, Italy.
  10. L. Sacco Department of Biomedical Sciences, University of Milan, Italy.

CER11810
2019 Vol.37, N°4 ,Suppl.119
PI 0125, PF 0132
Reviews

Free to view
(click on article PDF icon to read the article)

PMID: 30873947 [PubMed]

Received: 10/10/2018
Accepted : 07/01/2019
In Press: 27/02/2019
Published: 03/10/2019

Abstract

Systemic sclerosis (SSc) is an autoimmune disease characterised by tissue fibrosis leading to vascular injury. Nitric oxide (NO) has been implicated in the pathogenesis of autoimmune diseases. A deficiency in basal NO production by the constitutive endothelial isoform of nitric oxide synthase may promote vasoconstriction and vascular wall thickening. In January 2017, we searched the PubMed/Medline, Cochrane Library and Enbase/Medline databases for studies analysing physio-pathological correlations with lung fractional exhaled NO (FeNO) production. This review describes the rationale underlying possible applications of FeNO measurements in the management of SSc. Measuring NO levels at multiple expiratory flow rates makes it possible to distinguish airway NO production and distal airway/alveolar NO concentration (ANOC), and there is increasing evidence indicating that it may be useful in many non-respiratory conditions. FeNO levels are increased in SSc patients with fibrosing lung disease, whereas those with pulmonary hypertension have relatively low FeNO levels, thus suggesting that NO plays an important role in regulating pulmonary vascular resistance in SSc. However, a number of studies have shown increased ANOC in SSc patients without increased FeNO levels. The relationship between lung diffusing capacity for carbon monoxide and ANOC may be related to increased alveolar membrane thickness impeding NO diffusion or alveolar inflammation in SSc lung disease. The findings concerning the usefulness of FeNO measurements in SSc patients are discordant, but the available papers suggest that ANOC is a more accurate indicator of progressive lung dysfunction and an increase in ANOC could assess the extent of interstitial lung disease non-invasively.

Rheumatology Article